News >

FDA Approval Sought for Luspatercept for Anemias

Gina Columbus @ginacolumbusonc
Published: Friday, Apr 05, 2019

Jay Backstrom, MD

Jay Backstrom, MD

A supplemental biologics license application (sBLA) has been submitted to the FDA for luspatercept for the treatment of adult patients with very low- to intermediate-risk myelodysplastic syndrome (MDS)–associated anemia with ring sideroblasts who require red blood cell (RBC) transfusions, and also for adult patients with beta-thalassemia–associated anemia who require such transfusions.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x